Highlights & Basics
- Sjogren syndrome is a chronic inflammatory and autoimmune disorder characterized by diminished lacrimal and salivary gland secretion (sicca complex).
- May present with fatigue and dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).
- Diagnosed by positive antinuclear antibodies, anti-60 kD (SS-A) Ro and anti-La autoantibodies, decreased saliva and tear production, lymphocytic infiltration in labial salivary gland biopsy.
- Treatment is mainly symptomatic.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Foulks GN, Forstot SL, Donshik PC, et al. The Sjogren's Syndrome Foundation clinical practice guidelines. Ocular management in Sjogren's patients. 2015 [internet publication].[Full Text]
Vivino FB, Zero D, Brennan M, et al. Sjogren's Syndrome Foundation's clinical practice guidelines. Oral management: caries prevention in Sjogren's patients. 2015 [internet publication].[Full Text]
Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27.[Abstract][Full Text]
1. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol. 2013 Sep;9(9):544-56.[Abstract]
2. Fox PC. Autoimmune diseases and Sjogren's syndrome, an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007 Mar;1098:15-21.[Abstract]
3. Anaya JM, Tobon GJ, Vega P, et al. Autoimmune disease aggregation in families with primary Sjogren's syndrome. J Rheumatol. 2006 Nov;33(11):2227-34.[Abstract]
4. Steinberg AD, Talal N. The coexistence of Sjogren's syndrome and systemic lupus erythematosus. Ann Intern Med. 1971 Jan;74(1):55-61.[Abstract]
5. Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979 May;66(5):733-6.[Abstract]
6. Foster H, Fay A, Kelly C, et al. Thyroid disease and other autoimmune phenomena in a family study of primary Sjogren's syndrome. Br J Rheumatol. 1993 Jan;32(1):36-40.[Abstract]
7. Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, et al. Sjogren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med. 1974 Jul;57(1):78-85.[Abstract]
8. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov;74(11):1983-9.[Abstract]
9. Alani H, Henty JR, Thompson NL, et al. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018 Mar;47(2):141-54.[Abstract]
10. Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis. 2017 Jun;76(6):1042-50.[Abstract]
11. Fox RI. Sjogren's syndrome. Lancet. 2005 Jul 23-29;366(9482):321-31.[Abstract]
12. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol. 2006 May;2(5):252-61.[Abstract]
13. Maciel G, Crowson CS, Matteson EL, et al. Incidence and mortality of physician-diagnosed primary Sjögren syndrome: time trends over a 40-year period in a population-based US cohort. Mayo Clin Proc. 2017 May;92(5):734-43.[Abstract]
14. Baldini C, Mosca M, Della Rossa A, et al. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. 2013 Mar-Apr;31(2):272-80.[Abstract]
15. Salliot C, Mouthon L, Ardizzone M, et al. Sjogren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford). 2007 Feb;46(2):321-6.[Abstract][Full Text]
16. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006 May;2(5):262-9.[Abstract]
17. Gottenberg JE, Busson M, Loiseau P, et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003 Aug;48(8):2240-5.[Abstract]
18. Scofield RH. Genetics of systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol. 2009 Sep;21(5):448-53.[Abstract]
19. Nagata Y, Inoue H, Yamada K, et al. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology. 2004 Feb;111(2):223-9.[Abstract][Full Text]
20. Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. Transl Res. 2006 Dec;148(6):281-8.[Abstract]
21. Scheinfeld N. Sjogren syndrome and systemic lupus erythematosus are distinct conditions. Dermatol Online J. 2006 Jan 27;12(1):4.[Abstract][Full Text]
22. Hammi AR, Al-Hashimi IH, Nunn ME, et al. Assessment of SS-A and SS-B in parotid saliva of patients with Sjogren's syndrome. J Oral Pathol Med. 2005 Apr;34(4):198-203.[Abstract]
23. Lemp MA. Dry eye (keratoconjunctivitis sicca), rheumatoid arthritis, and Sjogren's syndrome. Am J Ophthalmol. 2005 Nov;140(5):898-9.[Abstract]
24. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001 Sep;2(9):777-80.[Abstract]
25. Ackerman LS. Sex hormones and the genesis of autoimmunity. Arch Dermatol. 2006 Mar;142(3):371-6.[Abstract]
26. Sullivan DA, Belanger A, Cermak JM, et al. Are women with Sjogren's syndrome androgen-deficient? J Rheumatol. 2003 Nov;30(11):2413-9.[Abstract]
27. Delaleu N, Jonsson R, Koller MM. Sjogren's syndrome. Eur J Oral Sci. 2005 Apr;113(2):101-13.[Abstract]
28. Liu K, Kurien BT, Zimmerman SL, et al. X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXX in systemic lupus erythematosus and Sjogren's syndrome. Arthritis Rheumatol. 2016 May;68(5):1290-1300.[Abstract][Full Text]
29. Harris VM, Sharma R, Cavett J, et al. Klinefelter's syndrome (47,XXY) is in excess among men with Sjogren's syndrome. Clin Immunol. 2016 Jul;168:25-29.[Abstract][Full Text]
30. Scofield RH, Kurien BT, Reichlin M. Immunologically restricted and inhibitory anti-Ro in monozygotic twins. Lupus. 1997;6(4):395-8.[Abstract]
31. Bolstad AI, Haga HJ, Wassmuth R, et al. Monozygotic twins with primary Sjogren's syndrome. J Rheumatol. 2000 Sep;27(9):2264-6.[Abstract]
32. Sumida T, Azuma N, Moriyama M, et al. Clinical practice guideline for Sjögren's syndrome 2017. Mod Rheumatol. 2018 May;28(3):383-408.[Abstract]
33. Romão VC, Talarico R, Scirè CA, et al. Sjögren's syndrome: state of the art on clinical practice guidelines. RMD Open. 2018 Oct 18;4(suppl 1):e000789.[Abstract][Full Text]
34. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis. 1994 Oct;53(10):637-47.[Abstract][Full Text]
35. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017 Jan;69(1):35-45.[Abstract][Full Text]
36. Foulks GN, Forstot SL, Donshik PC, et al. The Sjogren's Syndrome Foundation clinical practice guidelines. Ocular management in Sjogren's patients. 2015 [internet publication].[Full Text]
37. Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2004 Jun;18(3):313-29.[Abstract]
38. Fox PC, Brennan M, Pillemer S, et al. Sjogren's syndrome: a model for dental care in the 21st century. J Am Dent Assoc. 1998 Jun;129(6):719-28.[Abstract]
39. Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjogren's syndrome. Ann Rheum Dis. 1998 May;57(5):291-5.[Abstract][Full Text]
40. Gudbjornsson B, Broman JE, Hetta J, et al. Sleep disturbances in patients with primary Sjogren's syndrome. Br J Rheumatol. 1993 Dec;32(12):1072-6.[Abstract]
41. Rozis M, Vlamis J, Vasiliadis E, et al. Musculoskeletal manifestations in Sjogren's syndrome: an orthopedic point of view. J Clin Med. 2021 Apr 8;10(8):1574.[Abstract][Full Text]
42. Lei L, Morgan S, Ntatsaki E, et al. Comparative assessment of hand joint ultrasound findings in symptomatic patients with systemic lupus erythematosus and Sjögren's syndrome: a pilot study. Ultrasound Med Biol. 2019 Feb;45(2):452-60.[Abstract]
43. Colafrancesco S, Priori R, Gattamelata A, et al. Myositis in primary Sjögren's syndrome: data from a multicentre cohort. Clin Exp Rheumatol. 2015 Jul-Aug;33(4):457-64.[Abstract]
44. Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004 Mar;83(2):96-106.[Abstract][Full Text]
45. Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg. 2011 Jan-Feb;15(1):8-14.[Abstract]
46. Chapnick SL, Merkel PA. Skin ulcers in a patient with Sjögren's syndrome. Arthritis Care Res (Hoboken). 2010 Jul;62(7):1040-6.[Abstract][Full Text]
47. Guellec D, Cornec-Le Gall E, Groh M, et al. ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev. 2015 Aug;14(8):742-50.[Abstract]
48. Lu MC, Yin WY, Tsai TY, et al. Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan. PLoS One. 2013;8(10):e77210.[Abstract][Full Text]
49. Ramos-Casals M, García-Carrasco M, Cervera R, et al. Thyroid disease in primary Sjögren syndrome. Study in a series of 160 patients. Medicine (Baltimore). 2000 Mar;79(2):103-8.[Abstract][Full Text]
50. Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev. 2016 Jun;25(140):110-23.[Abstract][Full Text]
51. Ebert EC. Gastrointestinal and hepatic manifestations of Sjogren syndrome. J Clin Gastroenterol. 2012 Jan;46(1):25-30.[Abstract][Full Text]
52. Maury CP, Törnroth T, Teppo AM. Atrophic gastritis in Sjögren's syndrome. Morphologic, biochemical, and immunologic findings. Arthritis Rheum. 1985 Apr;28(4):388-94.[Abstract][Full Text]
53. Melchor S, Sánchez-Piedra C, Fernández Castro M, et al. Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögrenser registry. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):110-115.[Abstract]
54. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol. 1994 Aug;33(8):745-8.[Abstract][Full Text]
55. Montaño-Loza AJ, Crispín-Acuña JC, Remes-Troche JM, et al. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome. Ann Hepatol. 2007 Jul-Sep;6(3):150-5.[Abstract]
56. François H, Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol. 2016 Feb;12(2):82-93.[Abstract]
57. François H, Mariette X. Renal involvement in Sjögren's syndrome [in French]. Nephrol Ther. 2020 Dec;16(7):440-52.[Abstract]
58. Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. Am J Med. 2003 Jul;115(1):62-5.[Abstract]
59. Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol. 1994 Mar;170(3):835-7.[Abstract]
60. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004 Sep;83(5):280-91.[Abstract][Full Text]
61. Scofield AK, Radfar L, Ice JA, et al. Relation of sensory peripheral neuropathy in Sjogren syndrome to anti-Ro/SSA. J Clin Rheumatol. 2012 Sep;18(6):290-3.[Abstract]
62. Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):798-802.[Abstract]
63. Napeñas JJ, Rouleau TS. Oral complications of Sjogren's syndrome. Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):55-62.[Abstract]
64. Al-Hashimi I, Khuder S, Haghighat N, et al. Frequency and predictive value of the clinical manifestations in Sjogren's syndrome. J Oral Pathol Med. 2001 Jan;30(1):1-6.[Abstract]
65. Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002 Mar-Apr;33(2):95-106.[Abstract]
66. Klasser GD, Balasubramaniam R, Epstein J. Topical review-connective tissue diseases: orofacial manifestations including pain. J Orofac Pain. 2007 Summer;21(3):171-84.[Abstract]
67. Liao MT, Chien WC, Wang JC, et al. Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren's syndrome: nationwide population-based cohort study. BMJ Open. 2019 Feb 13;9(2):e024655.[Abstract][Full Text]
68. Seneff S, Swanson NL, Koenig G, et al. Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins. Dis Markers. 2016 Sep 28;2016:8376979.[Abstract][Full Text]
69. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8.[Abstract][Full Text]
70. Colella G, Cannavale R, Vicidomini A, et al. Salivary gland biopsy: a comprehensive review of techniques and related complications. Rheumatology (Oxford). 2010 Nov;49(11):2117-21.[Abstract]
71. Jonsson MV, Baldini C. Major salivary gland ultrasonography in the diagnosis of Sjogren's syndrome - a place in the diagnostic criteria? Rheum Dis Clin North Am. 2016 Aug;42(3):501-17.[Abstract]
72. Zhang X, Zhang S, He J, et al. Ultrasonographic evaluation of major salivary glands in primary Sjogren's syndrome: comparison of two scoring systems. Rheumatology (Oxford). 2015 Sep;54(9):1680-7.[Abstract][Full Text]
73. Luciano N, Baldini C, Tarantini G, et al. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjogren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015 Dec;54(12):2198-204.[Abstract]
74. Zabotti A, Zandonella Callegher S, Tullio A, et al. Salivary gland ultrasonography in Sjögren's syndrome: a European multicenter reliability exercise for the HarmonicSS project. Front Med (Lausanne). 2020;7:581248.[Abstract][Full Text]
75. Newbrun E. Current treatment modalities of oral problems of patients with Sjogren's syndrome: caries prevention. Adv Dent Res. 1996 Apr;10(1):29-34.[Abstract]
76. Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol. 2005 Mar 1;5(1):4.[Abstract][Full Text]
77. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004 Jun 28;164(12):1275-84.[Abstract][Full Text]
78. Tucci M, Quatraro C, Silvestris F. Sjogren's syndrome: an autoimmune disorder with otolaryngological involvement. Acta Otorhinolaryngol Ital. 2005 Jun;25(3):139-44.[Abstract][Full Text]
79. Segerberg-Konttinen M, Konttinen YT, Bergroth V. Focus score in the diagnosis of Sjogren's syndrome. Scand J Rheumatol Suppl. 1986;61:47-51.[Abstract]
80. Whitcher JP, Shiboski CH, Shiboski SC, et al; Sjogren's International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol. 2010 Mar;149(3):405-15.[Abstract]
81. Daniels TE, Benn DK. Is sialography effective in diagnosing the salivary component of Sjogren's syndrome? Adv Dent Res. 1996 Apr;10(1):25-8.[Abstract]
82. Nicholson DA. Contrast media in sialography: a comparison of Lipiodol Ultra Fluid and Urografin 290. Clin Radiol 1990 Dec;42(6):423-6.[Abstract]
83. Hernández-Molina G, Avila-Casado C, Nuñez-Alvarez C, et al. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjogren's syndrome in patients with systemic autoimmune diseases in the clinical setting. Rheumatology (Oxford). 2015 Mar;54(3):441-8.[Abstract]
84. Shiboski SC, Shiboski CH, Criswell L, et al; Sjogren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87.[Abstract][Full Text]
85. Lee AS, Scofield RH, Hammitt KM, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's. Chest. 2021 Feb;159(2):683-98.[Abstract][Full Text]
86. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010 Jul 28;304(4):452-60.[Abstract][Full Text]
87. Kalk WW, Mansour K, Vissink A, et al. Oral and ocular manifestations in Sjogren's syndrome. J Rheumatol. 2002 May;29(5):924-30.[Abstract]
88. Vivino FB, Zero D, Brennan M, et al. Sjogren's Syndrome Foundation's clinical practice guidelines. Oral management: caries prevention in Sjogren's patients. 2015 [internet publication].[Full Text]
89. Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep. 2005 Jul;5(4):327-32.[Abstract]
90. Jacobi C, Cursiefen C. Ophthalmological complications in Sjogren's syndrome [in German]. Z Rheumatol. 2010 Feb;69(1):32-40.[Abstract]
91. Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012 May;31(5):509-13.[Abstract]
92. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999 Apr;106(4):811-6.[Abstract][Full Text]
93. Hong S, Kim T, Chung SH, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. J Ocul Pharmacol Ther. 2007 Feb;23(1):78-82.[Abstract]
94. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Punctal occlusion in Sjogren's syndrome needs clarification. Nat Rev Rheumatol. 2012;8:752.[Abstract]
95. Zandbelt MM, van den Hoogen FH, de Wilde PC, et al. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren's syndrome. Ann Rheum Dis. 2001 May;60(5):511-3.[Abstract]
96. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren's syndrome. Clin Rev Allergy Immunol. 2007 Jun;32(3):284-91.[Abstract]
97. Mavragani CP, Moutsopoulos HM. Immunosuppression and immunomodulation in Sjogren's syndrome - what is the evidence? Does it relieve the sicca symptoms? Aktuelle Rheumatologie. 2005;30:66-70.
98. Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol. 1993 Mar-Apr;11(2):149-56.[Abstract]
99. Akpek EK, Lindsley KB, Adyanthaya RS, et al. Treatment of Sjogren's syndrome-associated dry eye: an evidence-based review. Ophthalmology. 2011 Jul;118(7):1242-52.[Abstract]
100. Gündüz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh). 1994 Aug;72(4):438-42.[Abstract]
101. Fan WS, Hung HL, Liao HP, et al. Topical cyclosporine therapy for keratoconjunctivitis sicca in Sjogren's syndrome. Tzu Chi Med J. 2003;15:85-89.
102. Drosos AA, Skopouli FN, Galanopoulu VK, et al. Cyclosporin A therapy in patients with primary Sjogren's syndrome: results at one year. Scand J Rheumatol Suppl. 1986;61:246-9.[Abstract]
103. Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis. 1986 Sep;45(9):732-5.[Abstract][Full Text]
104. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996 Sep-Oct;14(5):555-8.[Abstract]
105. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol. 1995 Apr;34(4):326-33.[Abstract]
106. Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008 Apr;37(5):273-92.[Abstract]
107. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol. 2006 Jul-Aug;35(4):323-5.[Abstract]
108. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014 Feb 18;160(4):233-42.[Abstract]
109. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58.[Abstract][Full Text]
110. Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27.[Abstract][Full Text]
111. Scofield RH. Vasculitis in Sjogren's Syndrome. Curr Rheumatol Rep. 2011 Dec;13(6):482-8.[Abstract]
112. Wakasugi D, Kato T, Gono T, et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome. Mod Rheumatol. 2009;19(4):437-40.[Abstract]
113. Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011 Sep;63(9):1339-44.[Abstract]
114. Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren's syndrome. J Neurol Sci. 2009 Apr 15;279(1-2):57-61.[Abstract]
115. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jan;97(1):28-46.[Abstract]
116. Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;(2):CD009327.[Abstract][Full Text]
117. López-García JS, García-Lozano I, Rivas L, et al. Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study. Acta Ophthalmol. 2014 Feb;92(1):e22-9.[Abstract][Full Text]
118. Kim BH, Kim MH, Kang SH, et al. Optimizing acupuncture treatment for dry eye syndrome: a systematic review. BMC Complement Altern Med. 2018 May 3;18(1):145.[Abstract][Full Text]
119. American College of Rheumatology. Guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic disease. Aug 2023 [internet publication].[Full Text]
120. American College of Rheumatology. 2023 American College of Rheumatology (ACR) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic disease. Aug 2023 [internet publication].[Full Text]
121. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023 Mar;75(3):449-64.[Abstract][Full Text]
122. Vivino FB, Al-Hashimi I, Khan Z, et al; P92-01 Study Group. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med. 1999 Jan 25;159(2):174-81.[Abstract][Full Text]
123. Harboe E, Tjensvoll AB, Maroni S, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis. 2009 Oct;68(10):1541-6.[Abstract]
124. Westhoff G, Dörner T, Zink A. Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study. Rheumatology (Oxford). 2012 Feb;51(2):262-9.[Abstract][Full Text]
125. Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol. 2007 Jun;32(3):265-74.[Abstract]
126. Fox RI. Sjogren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs. 2000 Sep;9(9):2007-16.[Abstract]
127. Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis. 2001 Nov;60(11):1007-10.[Abstract][Full Text]
128. Bartoloni E, Baldini C, Schillaci G, et al. Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. J Intern Med. 2015 Aug;278(2):185-92.[Abstract][Full Text]
129. Yong WC, Sanguankeo A, Upala S. Association between primary Sjögren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):190-7.[Abstract]
130. Berardicurti O, Ruscitti P, Cipriani P, et al. Cardiovascular disease in primary Sjögren's syndrome. Rev Recent Clin Trials. 2018;13(3):164-9.[Abstract]
131. Mofors J, Holmqvist M, Westermark L, et al. Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome. J Intern Med. 2019 Oct;286(4):458-68.[Abstract][Full Text]
